A high proportion of mutations in TP53 (44.8%), TET2 (24.1%), DNMT3A (13.8%), and NRAS (13.8%) were noted in this study of elderly Japanese patients with high-risk AML. This evidence concerns the gene TP53 and acute myeloid leukemia.